Ephedra ban lawsuit
This article was originally published in The Tan Sheet
Executive Summary
FDA is facing a second lawsuit over the ephedra ban by the marketer of Thermalean weight-loss supplement, according to a complaint filed in Birmingham, Ala. federal court March 23. The National Institute for Clinical Weight Loss alleges the agency did not meet its burden of proof in finding ephedra supplements presented unreasonable risk and violated the Administrative Procedures Act. NICW was barred from making drug claims for Thermalean under a 2003 consent decree (1"The Tan Sheet" Oct. 13, 2003, p. 4)...
You may also be interested in...
Dietary Supplement Obesity, Erectile Dysfunction Claims Barred By Court
An FDA consent decree barring the sale of dietary supplements purporting to treat obesity and erectile dysfunction follows repeated warnings to the marketers of the products, the agency announced Oct. 8
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.